The most pronounced reduction is in the substantia nigra, and in GBA1 mutation carriers (GCase activity loss of 58% in GBA1 mutation carriers vs. 33% in sporadic PD) (Gegg et al., 2012). The gene discussed is GBA1; the disease is Parkinson disease.